B-IMMUNE final analysis: a phase Ib/II study of durvalumab combined with dose-dense EC in neoadjuvant setting

Prof Duhoux from the oncology department of the King Albert II institute of the Cliniques Universitaires St.Luc, Brussels, presented a poster of the Belgian phase Ib/II study. In this B-IMMUNE study, the neo-adjuvant administration of a short course of an anti-PD-L1 (durvalumab) combined with anthracyclines after an initial treatment with taxanes was explored in patients with stage I to III luminal B HER2(-) or triple-negative breast cancer.